Interval Increase in the Prevalence of Symptomatic Cholelithiasis-associated Non-alcoholic Fatty Liver Disease over a Ten-year Period in an Asian Population

Overview

Journal Singapore Med J

Specialty General Medicine

Date 2016 Dec 21

PMID 27995261

Citations 4

Authors

Kevin Beng Chin Khaw

Rachel Huiyi Choi

Juinn Huar Kam

Bibhas Chakraborty

Pierce Kah Hoe Chow

Affiliations

Soon will be listed here.

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) is frequently associated with cholelithiasis. The prevalence of NAFLD in Asia has been on the rise, but the magnitude of this increase had not been studied previously.

Methods: A retrospective cohort study was conducted on consecutive patients who underwent laparoscopic or open cholecystectomy from November 2001 to November 2004 (Cohort 1) and from November 2011 to November 2014 (Cohort 2) at Singapore General Hospital. Preoperative diagnostic scans (e.g. ultrasonography, computed tomography and magnetic resonance imaging) and clinical data were reviewed for the presence of fatty liver. Statistical analysis was performed.

Results: In Cohorts 1 and 2, 127 patients and 99 patients were operated on, respectively. Cohort 2 had significantly higher proportions of patients with NAFLD (56.6% vs. 40.2%; p < 0.015) and hyperlipidaemia (45.5% vs. 18.9%; p < 0.001) as compared to Cohort 1. Binary logistic regression analysis showed that hypertension (odds ratio [OR] 2.558; p < 0.004) and Indian ethnicity (OR 5.448; p < 0.043) were significantly associated with NAFLD.

Conclusion: Similar to other international studies, we found a significant increase in the prevalence of patients with NAFLD presenting symptomatically for cholecystectomy over an interval of ten years in Singapore. Hypertension and Indian ethnicity were significantly associated with NAFLD in both time periods. This trend supports the need for concerted public health intervention to stem the increasing incidence of NAFLD and prevent its progression to more advanced liver disease.

Citing Articles

Systolic Blood Pressure Mediates Body Mass Index and Non-alcoholic Fatty Liver Disease: A Population-Based Study.

Guan X, Zhang Q, Xing J, Chen S, Wu S, Sun X Turk J Gastroenterol. 2021; 32(5):458-465.

PMID: 34231476 PMC: 8975508. DOI: 10.5152/tjg.2021.20641.

Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.

Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X Obes Facts. 2021; 14(2):190-196.

PMID: 33780962 PMC: 8138251. DOI: 10.1159/000514848.

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Sarin S, Kumar M, Eslam M, George J, Al Mahtab M, Akbar S Lancet Gastroenterol Hepatol. 2019; 5(2):167-228.

PMID: 31852635 PMC: 7164809. DOI: 10.1016/S2468-1253(19)30342-5.

Liver Disease in Singapore.

Muthiah M, Chong C, Lim S Euroasian J Hepatogastroenterol. 2018; 8(1):66-68.

PMID: 29963466 PMC: 6024054. DOI: 10.5005/jp-journals-10018-1262.

References

Loomba R, Sanyal A . The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90. DOI: 10.1038/nrgastro.2013.171. View

He Q, Horlick M, Thornton J, Wang J, Pierson Jr R, Heshka S . Sex and race differences in fat distribution among Asian, African-American, and Caucasian prepubertal children. J Clin Endocrinol Metab. 2002; 87(5):2164-70. DOI: 10.1210/jcem.87.5.8452. View

van Erpecum K . Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 2011; 35(4):281-7. DOI: 10.1016/j.clinre.2011.01.009. View

Ahmed M, Ali A . Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?. Scand J Gastroenterol. 2014; 49(5):521-7. DOI: 10.3109/00365521.2014.894119. View

Chen J, Hsu C, Liu J, Tung T . Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterol. 2014; 14:83. PMC: 4006445. DOI: 10.1186/1471-230X-14-83. View

de Bari O, Neuschwander-Tetri B, Liu M, Portincasa P, Wang D . Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2011; 2012:302847. PMC: 3216277. DOI: 10.1155/2012/302847. View

Loria P, Lonardo A, Lombardini S, Carulli L, Verrone A, Ganazzi D . Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005; 20(8):1176-84. DOI: 10.1111/j.1440-1746.2005.03924.x. View

Farrell G, Wong V, Chitturi S . NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307-18. DOI: 10.1038/nrgastro.2013.34. View

Smith B, Adams L . Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011; 7(8):456-65. DOI: 10.1038/nrendo.2011.72. View

10.

Chan W, Bahar N, Razlan H, Vijayananthan A, Sithaneshwar P, Goh K . Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males. Hepatol Int. 2015; 8(1):121-7. DOI: 10.1007/s12072-013-9510-8. View

11.

Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate A, Rasciti L . Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004; 53(7):1020-3. PMC: 1774102. DOI: 10.1136/gut.2003.027086. View

12.

Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T . Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014; 2(5):633-636. PMC: 4106613. DOI: 10.3892/br.2014.309. View

13.

Rinella M . Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22):2263-73. DOI: 10.1001/jama.2015.5370. View

14.

Farrell G, Chitturi S, Lau G, Sollano J . Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007; 22(6):775-7. DOI: 10.1111/j.1440-1746.2007.05002.x. View

15.

Deurenberg P, Deurenberg-Yap M, Guricci S . Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002; 3(3):141-6. DOI: 10.1046/j.1467-789x.2002.00065.x. View

16.

Chen L, Qiao Q, Zhang S, Chen Y, Chao G, Fang L . Metabolic syndrome and gallstone disease. World J Gastroenterol. 2012; 18(31):4215-20. PMC: 3422804. DOI: 10.3748/wjg.v18.i31.4215. View

17.

Lin I, Yang Y, Wu M, Yeh Y, Liou J, Lin Y . The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract. 2014; 15:138. PMC: 4118643. DOI: 10.1186/1471-2296-15-138. View

18.

Koller T, Kollerova J, Hlavaty T, Huorka M, Payer J . Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2011; 47(2):197-203. DOI: 10.3109/00365521.2011.643481. View

19.

Misra A, Vikram N . Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition. 2004; 20(5):482-91. DOI: 10.1016/j.nut.2004.01.020. View

20.

Wah-Kheong C, Khean-Lee G . Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. Hepatol Int. 2015; 7(1):65-71. DOI: 10.1007/s12072-012-9384-1. View